Trazodone label sharpens warnings around suicidality, rhythm risk, and serotonergic toxicity
Trazodone hydrochloride remains labeled for the treatment of major depressive disorder, but the updated DailyMed prescribing information places unusually heavy weight on safety monitoring from the first prescription onward. The boxed warning is explicit: antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients, and close monitoring is required for clinical worsening or emerging suicidality. Trazodone is not approved for pediatric use.
The medication’s place in practice is defined as much by caution as by efficacy. For clinicians treating depression, the label reads less like a routine dosing guide and more like a reminder that serotonergic drugs can destabilize vulnerable patients in multiple organ systems at once.
Dosing starts with divided administration and a slow upward titration
The recommended starting dose is 150 mg daily in divided doses. Dose increases may occur by 50 mg per day every three to four days, with a maximum of 400 mg per day in divided doses. Tablets should be taken shortly after a meal or light snack, swallowed whole, or broken in half along the score line, but not chewed or crushed.
This administration guidance matters because trazodone’s clinical effects and tolerability are closely tied to exposure. Divided dosing and food coadministration are intended to temper adverse effects while allowing therapeutic escalation in major depressive disorder. When treatment is stopped, gradual dose reduction is recommended, reflecting the potential for discontinuation symptoms and the practical difficulty of abrupt serotonergic withdrawal.
Serotonergic toxicity and cardiac effects sit near the center of the warning profile
A major warning in the label concerns serotonin syndrome. Risk rises when trazodone is combined with other serotonergic agents such as SSRIs, SNRIs, or triptans, but the syndrome can also occur with trazodone alone. If it develops, trazodone should be discontinued and supportive treatment initiated.
The physiology behind that warning is straightforward. Excess serotonergic activity can drive autonomic instability, neuromuscular abnormalities, and mental status changes, and the overlap with common psychiatric comedications makes the interaction clinically easy to miss. In real-world care, this warning is especially relevant when depression treatment is layered across multiple agents or when migraine therapy is already in place.
QT prolongation and arrhythmia risk form another major safety issue. The label states that trazodone increases the QT interval and should be avoided with other QT-prolonging drugs and in patients with risk factors for prolonged QT. For prescribers, that makes baseline medication reconciliation and cardiovascular risk review part of routine antidepressant stewardship rather than optional add-ons.
Orthostatic hypotension and syncope are also called out directly. For patients already prone to falls, dehydration, or autonomic instability, those effects can quickly turn a psychiatric prescription into a medical safety problem. Dizziness after standing, near-fainting, or actual syncope should be treated as clinically meaningful, not merely as nuisance adverse effects.
Bleeding, priapism, and mood switching require active surveillance
The label warns of an increased risk of bleeding when trazodone is used with aspirin, NSAIDs, antiplatelet drugs, warfarin, or other anticoagulants. Serotonergic agents can interfere with platelet function, so the concern extends beyond bruising and into clinically relevant hemorrhage when other hemostatic stressors are present.
Painful and prolonged penile erections, including priapism, have been reported. The warning is blunt for a reason: delayed recognition can cost erectile function and urologic emergency management may be required. Patients need explicit counseling because embarrassment often delays presentation.
Trazodone can also activate mania or hypomania. The label directs screening for bipolar disorder before treatment and ongoing monitoring afterward. In practice, that means a depressive presentation should never be treated as diagnostically fixed until bipolarity has been considered, particularly when sleep, energy, and impulsivity shift quickly after antidepressant exposure.
Cognitive impairment, eye risk, and sodium disturbances broaden the safety net
The label states that trazodone may impair judgment, thinking, and motor skills. That warning affects driving, machinery operation, and any setting where sedation or slowed reaction time can translate into injury. Drowsiness is one of the most common adverse reactions, along with fatigue, blurred vision, syncope, diarrhea, nasal congestion, edema, and weight loss.
Angle-closure glaucoma is another specific concern. Antidepressants, including trazodone, should be avoided in patients with untreated anatomically narrow angles. The mechanism is anatomical rather than psychiatric: medication-related changes in ocular dynamics can precipitate a dangerous pressure rise in a susceptible eye.
Hyponatremia appears in the safety section as well, expanding the label’s relevance to older adults and patients on other sodium-lowering therapies. Even without a quantified incidence in the text provided, the presence of this warning signals a need for electrolyte vigilance when confusion, weakness, or gait change appears after treatment begins.
Interaction management is built into the prescribing instructions
The interaction section is unusually practical. Trazodone may enhance the effects of alcohol, barbiturates, and other CNS depressants. Strong CYP3A4 inhibitors may require dose reduction based on tolerability, while CYP3A4 inducers may require an increase in trazodone dosage. The label also advises monitoring for increased digoxin or phenytoin levels and for increased or decreased prothrombin time with warfarin.
These warnings matter because trazodone is often prescribed in patients who already carry substantial medication burdens. Depression frequently coexists with chronic pain, cardiovascular disease, epilepsy, or substance use, and the interaction profile can shift the risk-benefit balance quickly. A stable psychiatric regimen can become unstable when a new antibiotic, anticonvulsant, anticoagulant, or sedative is added.
Repackaged labeling keeps the same core safety message
This repackaged label, updated in October 2026 and revised for presentation in DailyMed, does not introduce a new therapeutic claim. Instead, it reinforces the established prescribing boundaries around trazodone hydrochloride tablets, available as scored 50 mg, 100 mg, 150 mg, and 300 mg strengths. The medication remains an oral antidepressant for major depressive disorder, but the label makes clear that safe use depends on close attention to suicidality, serotonergic combinations, rhythm risk, hypotension, bleeding, and neurologic adverse effects.
For clinicians, the central issue is not whether trazodone can treat depression. The issue is whether the patient’s comedications, cardiovascular profile, ocular history, psychiatric history, and fall risk make the drug appropriate at all—and whether monitoring is tight enough once treatment starts.